Register
Login:
Share:
Email Facebook Twitter

EXCLUSIVE: Ascent CEO Colin Hutchinson with latest on review and permitting Watch Here

EXCLUSIVE: Ascent CEO Colin Hutchinson with latest on review and permitting


N4 Pharma Plc Share Price (N4P)



Share Price Information for N4 Pharma Plc (N4P)


Share Price: 8.05Bid: 7.60Ask: 8.50Change: 0.05 (+0.63%)Riser - N4 Pharma Plc
Spread: 0.90Spread as %: 11.84%Open: 8.00High: 8.05Low: 7.90Yesterday’s Close: 8.00

N4 Pharma Plc Ord 0.4P

N4 Pharma Plc is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
8.05
Share Price SpacerBid
7.60
Share Price SpacerAsk
8.50
Share Price SpacerChange
0.63%0.05
Share Price SpacerVolume
67,860
Share Price SpacerOpen
8.00
Share Price SpacerHigh
8.05
Share Price SpacerLow
7.90
Share Price SpacerClose
8.00
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 90.96m £7.32m 15,000

52 Week High 35.50 52 Week High Date 19-FEB-2018
52 Week Low 5.25 52 Week Low Date 25-OCT-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
8 30,621 37,239 -2.839 -2.84 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

16-Aug-18
14:09:26
7.73
6,546
Sell* 
7.60
8.50
506.01
Trade Type:
Ordinary

16-Aug-18
12:50:21
7.722
5,854
Sell* 
7.60
8.50
452.05
Trade Type:
Ordinary

16-Aug-18
11:52:38
8.29
5,609
Buy* 
7.50
8.50
464.99
Trade Type:
Ordinary




View more N4 Pharma Plc trades >>

Directors Deals for N4 Pharma Plc (N4P)
Trade DateActionNotifierPriceCurrencyAmountHolding
10-Nov-17Buy
Trade Notifier Information for N4 Pharma
Nigel Theobald held the position of CEO at N4 Pharma at the time of this trade.
 Nigel Theobald
7.92GBX56,65612255233
View more N4 Pharma Plc directors dealings >>


L.Leonardi
Posts: 13
Opinion:No Opinion
Price:8.05
RE: Strange
Today 15:04
Lol that’s true!
mazik
Posts: 1,438
Opinion:No Opinion
Price:8.05
RE: Strange
Today 13:11
U have bionic smell my friend, crash had already happened here 6 weeks ago:-) you get all sorts
bidnolid
Posts: 482
Opinion:No Opinion
Price:7.90
Article
Today 10:52
Off topic but a good article in the times today about the challenges of life on the alternative market. Views are not my etc etc so don't shoot the messenger and all that..

"One reason for listing on Aim is to attract institutional capital but increasingly those funds are raising their minimum market capitalisation requirements to £50 million and in many cases £100 million. Less than 25 per cent of Aim is valued at more than £100 million, meaning that 75 per cent falls beneath the radar of most institutional investors.

Increasingly, it is falling on the private investor to take up the slack but, even here, the regulatory hurdle for participation is increasing. Unless you are a private client with the highest attitude and affordability for risk, it is unlikely investing here will be considered suitable for you.

The net result is a growing void of investors for this market, often reflected in herd-like short-term momentum for share prices, followed by long periods in the wilderness. Most companies complain that they struggle to find quality longer-term investors and sensible valuations and find the whole exercise unsatisfactory.

Where the situation can become particularly difficult is for companies valued at less than £10 million — a quarter of the companies listed on Aim. The additional overhead required to list, which includes appointing a Nomad and hiring specialist accountants, lawyers, PRs and non-executive directors, can easily run to £200,000 a year. Given the size of these businesses, it is unlikely that many are making sufficient money to justify these costs."
L.Leonardi
Posts: 13
Opinion:No Opinion
Price:8.00
Strange
Today 09:25
smells like a stock market crash! Just saying.
mazik
Posts: 1,438
Opinion:No Opinion
Price:8.00
RE: AstraZeneca
Wed 16:41
Hah! Hah" Erective issue
View more share chat for N4 Pharma Plc (N4P) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.